Danaher

DHR

Market cap $160B

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.   NEW YORK , Nov. 28, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Danaher Corporation (NYSE: DHR) breached their fiduciary duties to shareholders.

Danaher (DHR) reported earnings 30 days ago. What's next for the stock?

These cheap stocks from wide-moat companies look attractive today.

Danaher Corporation ( DHR ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:00 AM EST Company Participants Rainer Blair - President, CEO & Director Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division I think we'll kick it off. Welcome, everybody.

As A.I. stocks take a beating on Wednesday's trading session, Dan Deming offers his thoughts and example options trades in healthcare and energy stocks. He explains his bullish theses behind Thermo Fisher Scientific (TMO), Danaher (DHR), and Valero Energy (VLO).

Investors interested in Medical Services stocks are likely familiar with Solventum (SOLV) and Danaher (DHR). But which of these two stocks offers value investors a better bang for their buck right now?

A biotech upstart and a life sciences giant could be compelling additions to an investor's portfolio. NovoCure is a high-risk but potentially high-reward bet on industry-changing technology.

WASHINGTON , Nov. 11, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Jefferies Global Healthcare Conference in London, UK on Tuesday, November 18, 2025 at 11:00 a.m.

Investors with an interest in Medical Services stocks have likely encountered both Solventum (SOLV) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?

The Top 15 High-Growth Dividend Stock list for November 2025 offers a 1.39% yield and 19.88% five-year dividend growth. Despite underperforming SPY and VIG in October, the watchlist targets a long-term 12% annual return and remains a strong starting point for research. Stocks are selected using Quality and Value tilts, aiming for higher yields, growth, and undervaluation, with an average 31% discount to fair value.